Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment

January 2026

Thank you to Madrigal for your support of this Medication Review Video Module.

In this medication review module, Michelle Barnett, PA-C, provides an in-depth overview of resmetirom, the first FDA-approved liver-directed thyroid hormone receptor beta (THR-β) agonist for adults with non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH) and moderate to advanced fibrosis (F2–F3). The discussion reviews MASH risk factors, resmetirom’s mechanism of action, dosing considerations, and key findings from the phase 3 MAESTRO-NASH trial, including improvements in liver histology and lipid parameters. Designed for APPs and clinicians, this concise review highlights how resmetirom fits into contemporary MASH management alongside lifestyle interventions such as diet and exercise.